Charles R. Eyler Sells 1,322 Shares of Puma Biotechnology Inc (PBYI) Stock
Puma Biotechnology Inc (NASDAQ:PBYI) insider Charles R. Eyler sold 1,322 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $105.46, for a total transaction of $139,418.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Puma Biotechnology Inc (NASDAQ:PBYI) traded down $4.40 during midday trading on Tuesday, reaching $93.85. 908,507 shares of the company’s stock were exchanged, compared to its average volume of 1,093,497. Puma Biotechnology Inc has a twelve month low of $28.35 and a twelve month high of $136.90.
Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) EPS for the quarter, beating analysts’ consensus estimates of ($2.50) by $0.43. The business had revenue of $6.10 million for the quarter, compared to the consensus estimate of $3.78 million. During the same quarter in the previous year, the business earned ($1.11) earnings per share. equities research analysts predict that Puma Biotechnology Inc will post -8.19 EPS for the current fiscal year.
Several research firms recently weighed in on PBYI. BidaskClub cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 14th. Credit Suisse Group upped their price objective on shares of Puma Biotechnology from $136.00 to $142.00 and gave the stock an “outperform” rating in a research report on Friday, November 10th. Barclays restated a “buy” rating and issued a $122.00 price objective (up from $103.00) on shares of Puma Biotechnology in a research report on Friday, November 10th. Citigroup upped their price objective on shares of Puma Biotechnology from $156.00 to $164.00 and gave the stock a “buy” rating in a research report on Friday, November 10th. Finally, Royal Bank Of Canada decreased their price objective on shares of Puma Biotechnology from $108.00 to $92.00 and set a “sector perform” rating on the stock in a research report on Friday, November 10th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $130.67.
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.